netFormulary
 Report : Medicines with links to NICE 13/11/2018 21:57:57

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abiraterone 08.03.04.02 Restricted Use NICE TA259: Abiraterone for treating metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen
Acitretin 13.05.02 Restricted Use NICE CG153: Psoriasis - assessment and management
Adalimumab 10.01.03 Restricted Use NICE TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severeley active ulcerative colitis after failure of conventional therapy
Adalimumab 01.05.03 Restricted Use TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 13.05.03 Restricted Use NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Aflibercept 11.08.02 Formulary NICE TA486 Aflibercept for treating choroidal neovascularisation
Aflibercept 11.08.02 Formulary NICE TA486 Aflibercept for treating choroidal neovascularisation
Aflibercept 11.08.02 Formulary NICE TA294 Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA346 Aflibercept for treating diabetic macular oedema
Alirocumab 20.01 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Restricted Use NICE guidelines - Alitretinoin for chronic eczema
Apixaban 02.08.02 Formulary NICE guidance: Apixaban for the prevention of VTE after total hip or knee replacement in adults
Baricitinib 10.01.03 Restricted Use NICE TA466 Baricitinib for moderate to severe rheumatoid arthritis
Brodalumab 13.05.02 Formulary NICE TA511 - Brodalumab for treating moderate to severe plaque psoriasis
Calcipotriol 50micrograms/g with Betamethasone 0.05% 13.05.02 Formulary NICE CG153: The assessment and management of psoriasis
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Cetuximab 08.01.05 Restricted Use NICE TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Ciclosporin 13.05.03 Formulary NICE CG153: Psoriasis - assessment and management
Ciclosporin 1mg/mL Eye Drops 11.08.01 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Colesevelam 02.12 Restricted Use NICE evidence review: Colesevelam for bile acid malabsorption
Collagenase clostridium histolyticum 10.03.01 Formulary NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Dabigatran 02.08.02 Formulary NICE TA 327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for the treatment and secondary prevention of stroke and systemic embolism in atrial fibrilation
Dabrafenib 08.01.05 Formulary NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dexamethasone 11.04.02 Formulary NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis
Donepezil Hydrochloride 04.11 Restricted Use NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Dulaglutide 06.01.02.03 Formulary NICE ESNM59: Dulaglutide for Type 2 Diabetes
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and preventing DVT and PE
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and embolism in people with non-valvular AF
Eltrombopag 09.01.04 Restricted Use NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic perpura
Eluxadoline 01.04.02 Restricted Use NICE TA471 - Eluxadoline (Truberzi) for treating irritable bowel syndrome with diarrhoea in adults
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Etanercept 10.01.03 Restricted Use TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 13.05.03 Restricted Use NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 13.05.03 Restricted Use NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 10.01.03 Restricted Use - TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etelcalcetide 06.06.01 Restricted Use NICE TA448 Etelcalcetide for treating secondary hyperparathyroidism
Evolocumab 20.01 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Fulvestrant 08.03.04.01 Restricted Use NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Galantamine 04.11 Restricted Use NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Galantamine 04.11 Restricted Use NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Golimumab 01.05.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Guselkumab 13.05.03 Formulary NICE TA521 Guselkumab for treating moderate to severe plaque psoriasis
Idelalisib 100mg and 150mg tablets 20.01 Restricted Use NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Infliximab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severeley active ulcerative colitis after failure of conventional therapy
Isosorbide Mononitrate 02.06.01 Formulary NICE CG126: Stable angina
Ivabradine 02.06.03 Restricted Use NICE CG126: Stable angina
Ivabradine 02.06.03 Restricted Use NICE TA267: Ivabradine for treating chronic heart failure
Ixekizumab 80mg solution for injection 13.01 Formulary NICE TA442 - Ixekizumab for treating moderate to severe plaque psoriasis
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lesinurad 10.01.04 Non Formulary NICE TA506 Lesinurad for treating chronic hyperuricaemia in people with gout
Linaclotide 01.06.07 Restricted Use NICE ESNM16: Irritable bowel syndrome with constipation in adults: linaclotide
Liraglutide 06.01.02.03 Formulary NICE guidance 28 - Type 2 dibetes in adults: management
Lubiprostone 01.06.07 Formulary NICE TA318 Lubiprostone for treating chronic idiopathic constipation
Memantine Hydrochloride 04.11 Formulary NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Mepolizumab 03.04.02 Restricted Use NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Methotrexate 13.05.03 Restricted Use NICE CG153: Psoriasis - assessment and management
Naloxegol oxalate 01.06 Formulary NICE TA345: Naloxegol for treating opioid-induced constipation
Obeticholic acid 01.09.01 Formulary NICE TA443 Obeticholic acid for treating primary biliary cholangitis
Omalizumab 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Restricted Use NICE TA278: Omalizumab for treating severe persistent asthma
Pemetrexed 08.01.03 Formulary TA190 (updated from June 2010) - Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Pomalidomide 08.02.04 Restricted Use NICE TA338: Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib
Prucalopride 01.06.07 Restricted Use NICE TA211: Prucalopride for constipation in women
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ranibizumab 11.08.02 Formulary NICE TA274 Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab 11.08.02 Formulary NICE TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranibizumab 11.08.02 Formulary NICE TA283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranolazine 02.06.03 Formulary NICE CG126: Stable angina
Reslizumab 03.04.02 Restricted Use NICE TA479 Reslizumab for treating severe eosinophilic asthma
Rifaximin 550mg tablets 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE guidance: Rivaroxaban for the treatment of deep vein thrombosis and the prevention of recurrent DVT and PE
Rivastigmine 04.11 Restricted Use NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Roflumilast 03.03.03 Formulary TA461 - Roflumilast for treating chronic obstructive pulmonary disease
Sacubitril/valsartan 02.05.05.02 Formulary TA 388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 10.01.03 Restricted Use NICE TA485 Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 20.01 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 20.01 Formulary NICE TA350:Secukinumab for treating moderate to severe plaque psoriasis
Teriparatide 06.06.01 Restricted Use NICE TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ticagrelor 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tocilizumab 10.01.03 Restricted Use NICE TA518 - Tocilizumab for treating giant cell arteritis
Tocilizumab 10.01.03 Restricted Use NICE TA518 - Tocilizumab for treating giant cell arteritis
Tofacitinib 10.01.03 Restricted Use NICE TA480 Tofacitinib for moderate to severe rheumatoid arthritis
Tolvaptan 06.05.02 Restricted Use NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Trastuzumab emtansine 08.01.05 Restricted Use TA458 - Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Ustekinumab 13.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Formulary NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 13.05.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Formulary - TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severley active ulcerative colitis
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Harrogate & Rural District Formulary